Abstract: The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.

Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.

Abstract: Disclosed herein are methods for detecting a target nucleic acid molecule in a sample. The methods can include contacting a sample with a detectably labeled probe (detection probe) that specifically binds to a first target sequence in the target nucleic acid molecule, a bifunctional oligonucleotide including a portion that specifically binds to a second target sequence in the target nucleic acid molecule and a portion that specifically binds to an anchor, and a surface comprising the anchor. Specifically bound detection probe and bifunctional oligonucleotide are ligated and a reagent that specifically removes substantially all of the target nucleic acid is added. Unligated detection probe is removed and presence of the detectable label is detected. In other embodiments, the ligation and/or removal of target nucleic acid are omitted and the detection probe specifically bound to the target nucleic acid is detected.

Abstract: The invention relates to compositions and methods for detecting renal injury in a subject, such as proximal tubular injury associated with acute kidney injury.

Abstract: This disclosure concerns the identification of biomarkers that are characteristic of squamous or non squamous (e.g., adenocarcinoma, large cell carcinoma, carcinoid tumor, sarcomatoid carcinoma) subtypes of non small cell lung cancer (NSCLC), clinically useful NSCLC classifiers, kits and arrays for distinguishing squamous and nonsquamous NSCLC subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing.

Abstract: Evaluation of VLP-1 levels in combination with at least one of amyloid-? peptide (A?), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.

Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.

Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: A method for aiding in the determination of whether a living or deceased human is afflicted with or will likely have atherosclerosis respectfully, the method comprising determining the level of SPRR3 protein in a intimae or body fluid sample by using molecular localization analysis technique comparing the determined level of SPRR3 protein in the biological sample obtained from said individual with a range of SPRR3 levels previously defined as characteristic for humans having atherosclerosis, concluding from the comparison that the person is likely suffering from atherosclerosis when a SPRR3 level is in the range previously defined as characteristic for the presence of atherosclerosis as an indication that the individual is suffering from or has suffered from atherosclerosis.

Abstract: Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed.

Abstract: A method for aiding in the determination of whether a living or deceased human is afflicted with or will likely have atherosclerosis respectfully, the method comprising determining the level of SPRR3 protein in a intimae or body fluid sample by using molecular localization analysis technique comparing the determined level of SPRR3 protein in the biological sample obtained from said individual with a range of SPRR3 levels previously defined as characteristic for humans having atherosclerosis, concluding from the comparison that the person is likely suffering from atherosclerosis when a SPRR3 level is in the range previously defined as characteristic for the presence of atherosclerosis as an indication that the individual is suffering from or has suffered from atherosclerosis.